Thompson Siegel & Walmsley LLC Has $14.13 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Thompson Siegel & Walmsley LLC increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 107.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 157,964 shares of the medical equipment provider's stock after acquiring an additional 81,680 shares during the quarter. Thompson Siegel & Walmsley LLC owned approximately 0.23% of Lantheus worth $14,131,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of LNTH. Vestcor Inc increased its position in shares of Lantheus by 9.7% in the fourth quarter. Vestcor Inc now owns 6,653 shares of the medical equipment provider's stock worth $595,000 after acquiring an additional 591 shares in the last quarter. Swiss National Bank grew its position in Lantheus by 1.0% during the 4th quarter. Swiss National Bank now owns 136,654 shares of the medical equipment provider's stock worth $12,225,000 after purchasing an additional 1,300 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Lantheus during the 4th quarter worth approximately $237,000. Avantax Advisory Services Inc. raised its stake in Lantheus by 5.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock valued at $213,000 after purchasing an additional 132 shares during the period. Finally, Prosperity Financial Group Inc. lifted its holdings in shares of Lantheus by 13.9% in the fourth quarter. Prosperity Financial Group Inc. now owns 4,712 shares of the medical equipment provider's stock valued at $422,000 after purchasing an additional 575 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Lantheus Stock Down 0.5 %

LNTH stock traded down $0.54 during mid-day trading on Tuesday, reaching $102.22. 530,077 shares of the stock traded hands, compared to its average volume of 939,616. The business has a 50-day moving average of $92.25 and a two-hundred day moving average of $96.67. The firm has a market capitalization of $7.00 billion, a PE ratio of 17.01 and a beta of 0.38. Lantheus Holdings, Inc. has a 52 week low of $56.44 and a 52 week high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. StockNews.com downgraded Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Truist Financial lifted their target price on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. The Goldman Sachs Group assumed coverage on Lantheus in a report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price objective for the company. Finally, JMP Securities reiterated a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $132.86.

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 54,109 shares of company stock valued at $5,105,606. 1.50% of the stock is owned by company insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.